L&C Bio (290650.KQ) said Thursday it will expand production capacity of its extracellular matrix (ECM) regenerative medical material "Lituo" to ensure stable supply and accelerate overseas expansion. The company expects the ECM-based treatment market to reach a new stage of growth as Lituo supply normalizes.
Since its launch in November 2024, Lituo has seen rapidly rising demand primarily through hospital and clinic channels, resulting in limited supply. To stabilize supply, L&C Bio pursued expansion of its production facilities and on Thursday obtained an additional Good Tissue Practice (GTP) facility permit from the Gyeongin Regional Office of Food and Drug Safety.
L&C Bio plans to gradually increase Lituo supply starting in May after completing product validation at the new facility. Monthly production capacity will expand from approximately 30,000 units to a total of 80,000 units.
Alongside the capacity expansion, L&C Bio is pursuing overseas market entry in parallel. The company said it has completed or is in the process of obtaining product approvals in approximately 20 countries including Mongolia, Hong Kong, Peru and Australia, with plans to expand overseas supply volumes starting in the second half of the year.
L&C Bio is also reviewing further production facility expansion targeting October this year. If the plan is completed, the company expects to secure maximum monthly production capacity of more than 150,000 units within the year.
